Cross-border life sciences partnerships have become one of the most powerful and complex routes to innovation. As deal activity involving Chinese biotech assets accelerates, companies are facing faster timelines, more sophisticated structures, new sources of pricing and regulatory uncertainty – reshaping how these transactions are crafted and executed.

While innovation remains the catalyst, success increasingly depends on execution. Successful companies are adapting quickly: rethinking the way deals are sourced, negotiated and structured to keep up with the evolving realities of the related marketing.

Life sciences leaders pursuing cross-border partnerships in this increasingly complex landscape should keep in mind the below themes when approaching the table:

Cross-border deal activity is accelerating.

There has been a significant improvement in the quality and maturity of assets emerging from China over the past decade, particularly in oncology and biologics. Faster generation of human clinical data and strong scientific execution have made Chinese biotech a compelling source of global partnering opportunities.

Deal timelines are compressing.

Competition for differentiated assets has led to increasingly compressed deal timelines. Parties often move quickly from initial evaluation to exclusivity, with negotiations that once took many months now closing in weeks. While speed can preserve momentum, it puts pressure on diligence and documentation.

Innovation is increasing structural complexity.

Advances in biologics are adding complexity to deal structures. Agreements must now address sophisticated development paths, manufacturing considerations and governance mechanisms tailored to these modalities.

MFN-related uncertainty is reshaping negotiations.

Emerging most-favored-nation (MFN)-style concerns related to pricing and policy have injected new uncertainty into dealmaking. Parties are increasingly negotiating trigger-based adjustments, conditional shifts in control, and financial consequences tied to future regulatory or pricing developments.

Cross‑border life sciences partnerships are no longer the exception – they are a core strategy for accessing innovation. The challenge is building them for resilience: balancing speed with structure, competition with collaboration and short‑term deal pressure with long‑term operational reality.

Preparing for a global alliance and ready to learn more about Cooley’s services? Get in touch with us.

Related insights

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.